Differential effects of tyrosine kinase inhibitors in haemostasis, thrombosis and inflammation

The detection of the Bcr-Abl gene in chronic myeloid leukaemia (CML) has resulted in the development of novel tyrosine kinase inhibitors (TKIs), such as imatinib that particularly interfere with the ATP binding pocket of the Abl kinase domain of the Bcr-A